Strikingly, sustained tumor cell proliferation after preoperative endocrine therapy (post-pET Ki67 ≥10%) was associated with TP53 mutation in non-lobular BC (Fig. 4A) but with ERBB2 mutation in ILC (Fig. 4B). Here, TP53 is linked to breast cancer.